Epinephrine in Out-of-Hospital Cardiac Arrest : A Network Meta-analysis and Subgroup Analyses of Shockable and Nonshockable Rhythms
Copyright © 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Epinephrine is the most commonly used drug in out-of-hospital cardiac arrest (OHCA) resuscitation, but evidence supporting its efficacy is mixed.
RESEARCH QUESTION: What are the comparative efficacy and safety of standard dose epinephrine, high-dose epinephrine, epinephrine plus vasopressin, and placebo or no treatment in improving outcomes after OHCA?.
STUDY DESIGN AND METHODS: In this systematic review and network meta-analysis of randomized controlled trials, we searched six databases from inception through June 2022 for randomized controlled trials evaluating epinephrine use during OHCA resuscitation. We performed frequentist random-effects network meta-analysis and present ORs and 95% CIs. We used the the Grading of Recommendations, Assessment, Development, and Evaluation approach to rate the certainty of evidence. Outcomes included return of spontaneous circulation (ROSC), survival to hospital admission, survival to discharge, and survival with good functional outcome.
RESULTS: We included 18 trials (21,594 patients). Compared with placebo or no treatment, high-dose epinephrine (OR, 4.27; 95% CI, 3.68-4.97), standard-dose epinephrine (OR, 3.69; 95% CI, 3.32-4.10), and epinephrine plus vasopressin (OR, 3.54; 95% CI, 2.94-4.26) all increased ROSC. High-dose epinephrine (OR, 3.53; 95% CI, 2.97-4.20), standard-dose epinephrine (OR, 3.00; 95% CI, 2.66-3.38), and epinephrine plus vasopressin (OR, 2.79; 95% CI, 2.27-3.44) all increased survival to hospital admission as compared with placebo or no treatment. However, none of these agents may increase survival to discharge or survival with good functional outcome as compared with placebo or no treatment. Compared with placebo or no treatment, standard-dose epinephrine improved survival to discharge among patients with nonshockable rhythm (OR, 2.10; 95% CI, 1.21-3.63), but not in those with shockable rhythm (OR, 0.85; 95% CI, 0.39-1.85).
INTERPRETATION: Use of standard-dose epinephrine, high-dose epinephrine, and epinephrine plus vasopressin increases ROSC and survival to hospital admission, but may not improve survival to discharge or functional outcome. Standard-dose epinephrine improved survival to discharge among patients with nonshockable rhythm, but not those with shockable rhythm.
TRIAL REGISTRY: Center for Open Science: https://osf.io/arxwq.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Chest - 164(2023), 2 vom: 01. Aug., Seite 381-393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernando, Shannon M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11000-17-2 |
|---|
| Anmerkungen: |
Date Completed 11.08.2023 Date Revised 15.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.chest.2023.01.033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352465123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352465123 | ||
| 003 | DE-627 | ||
| 005 | 20231226053804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.chest.2023.01.033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352465123 | ||
| 035 | |a (NLM)36736487 | ||
| 035 | |a (PII)S0012-3692(23)00165-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fernando, Shannon M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epinephrine in Out-of-Hospital Cardiac Arrest |b A Network Meta-analysis and Subgroup Analyses of Shockable and Nonshockable Rhythms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2023 | ||
| 500 | |a Date Revised 15.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Epinephrine is the most commonly used drug in out-of-hospital cardiac arrest (OHCA) resuscitation, but evidence supporting its efficacy is mixed | ||
| 520 | |a RESEARCH QUESTION: What are the comparative efficacy and safety of standard dose epinephrine, high-dose epinephrine, epinephrine plus vasopressin, and placebo or no treatment in improving outcomes after OHCA? | ||
| 520 | |a STUDY DESIGN AND METHODS: In this systematic review and network meta-analysis of randomized controlled trials, we searched six databases from inception through June 2022 for randomized controlled trials evaluating epinephrine use during OHCA resuscitation. We performed frequentist random-effects network meta-analysis and present ORs and 95% CIs. We used the the Grading of Recommendations, Assessment, Development, and Evaluation approach to rate the certainty of evidence. Outcomes included return of spontaneous circulation (ROSC), survival to hospital admission, survival to discharge, and survival with good functional outcome | ||
| 520 | |a RESULTS: We included 18 trials (21,594 patients). Compared with placebo or no treatment, high-dose epinephrine (OR, 4.27; 95% CI, 3.68-4.97), standard-dose epinephrine (OR, 3.69; 95% CI, 3.32-4.10), and epinephrine plus vasopressin (OR, 3.54; 95% CI, 2.94-4.26) all increased ROSC. High-dose epinephrine (OR, 3.53; 95% CI, 2.97-4.20), standard-dose epinephrine (OR, 3.00; 95% CI, 2.66-3.38), and epinephrine plus vasopressin (OR, 2.79; 95% CI, 2.27-3.44) all increased survival to hospital admission as compared with placebo or no treatment. However, none of these agents may increase survival to discharge or survival with good functional outcome as compared with placebo or no treatment. Compared with placebo or no treatment, standard-dose epinephrine improved survival to discharge among patients with nonshockable rhythm (OR, 2.10; 95% CI, 1.21-3.63), but not in those with shockable rhythm (OR, 0.85; 95% CI, 0.39-1.85) | ||
| 520 | |a INTERPRETATION: Use of standard-dose epinephrine, high-dose epinephrine, and epinephrine plus vasopressin increases ROSC and survival to hospital admission, but may not improve survival to discharge or functional outcome. Standard-dose epinephrine improved survival to discharge among patients with nonshockable rhythm, but not those with shockable rhythm | ||
| 520 | |a TRIAL REGISTRY: Center for Open Science: https://osf.io/arxwq | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a critical care medicine | |
| 650 | 4 | |a emergency medicine | |
| 650 | 4 | |a epinephrine | |
| 650 | 4 | |a out-of-hospital cardiac arrest | |
| 650 | 4 | |a return of spontaneous circulation | |
| 650 | 7 | |a Epinephrine |2 NLM | |
| 650 | 7 | |a YKH834O4BH |2 NLM | |
| 650 | 7 | |a Vasopressins |2 NLM | |
| 650 | 7 | |a 11000-17-2 |2 NLM | |
| 700 | 1 | |a Mathew, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghirad, Behnam |e verfasserin |4 aut | |
| 700 | 1 | |a Rochwerg, Bram |e verfasserin |4 aut | |
| 700 | 1 | |a Hibbert, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Munshi, Laveena |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Eddy |e verfasserin |4 aut | |
| 700 | 1 | |a Brodie, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Di Santo, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a McLeod, Shelley L |e verfasserin |4 aut | |
| 700 | 1 | |a Vaillancourt, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Cheskes, Sheldon |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson, Niall D |e verfasserin |4 aut | |
| 700 | 1 | |a Scales, Damon C |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Sandroni, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Soar, Jasmeet |e verfasserin |4 aut | |
| 700 | 1 | |a Dorian, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Perkins, Gavin D |e verfasserin |4 aut | |
| 700 | 1 | |a Nolan, Jerry P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chest |d 1970 |g 164(2023), 2 vom: 01. Aug., Seite 381-393 |w (DE-627)NLM000002720 |x 1931-3543 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:2 |g day:01 |g month:08 |g pages:381-393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.chest.2023.01.033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 2 |b 01 |c 08 |h 381-393 | ||